FDA to Highlight Aging, Longevity Medicine in Planned FARS Update
FDA Chief Scientist Steven Kozlowski, MD, said the updated FARS would come out early in FY 2027 but offered no further specifics on timing. The post FDA to Highlight Aging, Longevity Medicine in Planned FARS Update appeared first on GEN - Genetic Engineering and Biotechnology News .
The FDA's top scientific official, Steven Kozlowski, MD, drew applause at a longevity medicine conference by announcing the agency's intention to focus on aging and longevity in its upcoming Focus Areas of Regulatory Science (FARS) report. Kozlowski emphasized the importance of quantifying aging's impact on chronic diseases and developing feasible clinical trial designs to study it.
Acting FDA Chief of Staff Lowell M. Zeta highlighted the significance of longevity and healthspan in the agency and the Department of Health and Human Services (HHS). Panel moderator Andrew Brack, PhD, introduced the discussion on the most realistic regulatory path to develop therapies targeting aging biology, with FDA officials proposing different approaches to consider aging in new therapies and using clinical trials to demonstrate the impact on aging-related domains.
Written by urgent.news from GEN Biotechnology's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
